Jornadas HM Gabinete Velázquez logo

 

Información del ponente

Dr Eva M. Ciruelos is Medical Oncologist and Coordinator of the Multidisciplinary Breast Cancer Unit at the University Hospital 12 de Octubre in Madrid, Spain. She is current coordinator of Breast Cancer Unit at HM private hospitals in Madrid. Additionally, she is an Associate Professor in the Department of Medicine at the Complutense University of Madrid Faculty of Medicine since 2008.
Medical degree at the Autonoma University of Madrid (1996), Spain, and Medical Oncology training in Medical Oncology at the University Hospital 12 de Octubre (2001). She received her Doctorate in internal medicine at the Complutense University of Madrid Faculty of Medicine (2004).
Dr Ciruelos is the Principal Investigator of several clinical trials and research projects in breast cancer, and has received many public grants from Instituto de Salud Carlos III and other public and private organisations. She is the current vicepresident of the Solid Tumor Intensification (SOLTI) Group and serves on several committees for that organisation. She is also a member of the scientific Committee of the Breast International Group (BIG) and has been member of the St Gallen Conference Pannel since 2017. She is author and reviewer of many Oncology practice guidelines with national (Spanish Society of Medical Oncology) and international impact.
She is member of many Steering Committees of registration clinical trials and author of current national and international guidelines on management of breast cancer.
Dr Ciruelos has contributed to many oncology textbook chapters, and is author or co-author of numerous articles that have been published in indexed journals (www.pubmed.com) focus on breast cancer research; she also is a KOL on breast cancer and plays an active role in medical education events.

Tu valoración

Patrocinadores

APP OFICIAL DE LAS JORNADAS 2021

Ya disponible la APP oficial para la edición 2021 en iOs y Android!



image Este sitio web usa cookies propias y de terceros. Si continúas navegando consideramos que aceptas su uso. Aceptar